PMID- 11978788 OWN - NLM STAT- MEDLINE DCOM- 20020806 LR - 20210209 IS - 0021-9258 (Print) IS - 0021-9258 (Linking) VI - 277 IP - 26 DP - 2002 Jun 28 TI - Activation of the ERK pathway and atypical protein kinase C isoforms in exercise- and aminoimidazole-4-carboxamide-1-beta-D-riboside (AICAR)-stimulated glucose transport. PG - 23554-62 AB - Exercise increases glucose transport in muscle by activating 5'-AMP-activated protein kinase (AMPK), but subsequent events are unclear. Presently, we examined the possibility that AMPK increases glucose transport through atypical protein kinase Cs (aPKCs) by activating proline-rich tyrosine kinase-2 (PYK2), ERK pathway components, and phospholipase D (PLD). In mice, treadmill exercise rapidly activated ERK and aPKCs in mouse vastus lateralis muscles. In rat extensor digitorum longus (EDL) muscles, (a) AMPK activator, 5-aminoimidazole-4-carboxamide-1-beta-d-riboside (AICAR), activated PYK2, ERK and aPKCs; (b) effects of AICAR on ERK and aPKCs were blocked by tyrosine kinase inhibitor, genistein, and MEK1 inhibitor, PD98059; and (c) effects of AICAR on aPKCs and 2-deoxyglucose (2-DOG) uptake were inhibited by genistein, PD98059, and PLD-inhibitor, 1-butanol. Similarly, in L6 myotubes, (a) AICAR activated PYK2, ERK, PLD, and aPKCs; (b) effects of AICAR on ERK were inhibited by genistein, PD98059, and expression of dominant-negative PYK2; (c) effects of AICAR on PLD were inhibited by MEK1 inhibitor UO126; (d) effects of AICAR on aPKCs were inhibited by genistein, PD98059, 1-butanol, and expression of dominant-negative forms of PYK2, GRB2, SOS, RAS, RAF, and ERK; and (e) effects of AICAR on 2DOG uptake/GLUT4 translocation were inhibited by genistein, PD98059, UO126, 1-butanol, cell-permeable myristoylated PKC-zeta pseudosubstrate, and expression of kinase-inactive RAF, ERK, and PKC-zeta. AMPK activator dinitrophenol had effects on ERK, aPKCs, and 2-DOG uptake similar to those of AICAR. Our findings suggest that effects of exercise on glucose transport that are dependent on AMPK are mediated via PYK2, the ERK pathway, PLD, and aPKCs. FAU - Chen, Hubert C AU - Chen HC AD - James A. Haley Veterans Hospital and the Department of Internal Medicine, University of South Florida College of Medicine, Tampa, Florida 33612, USA. FAU - Bandyopadhyay, Gautam AU - Bandyopadhyay G FAU - Sajan, Mini P AU - Sajan MP FAU - Kanoh, Yoshinori AU - Kanoh Y FAU - Standaert, Mary AU - Standaert M FAU - Farese, Robert V Jr AU - Farese RV Jr FAU - Farese, Robert V AU - Farese RV LA - eng GR - R01 DK065969/DK/NIDDK NIH HHS/United States PT - Journal Article DEP - 20020426 PL - United States TA - J Biol Chem JT - The Journal of biological chemistry JID - 2985121R RN - 0 (Isoenzymes) RN - 0 (Ribonucleotides) RN - 360-97-4 (Aminoimidazole Carboxamide) RN - EC 2.7.11.13 (Protein Kinase C) RN - EC 2.7.11.24 (Mitogen-Activated Protein Kinases) RN - EC 3.1.4.4 (Phospholipase D) RN - F0X88YW0YK (AICA ribonucleotide) RN - IY9XDZ35W2 (Glucose) SB - IM MH - Aminoimidazole Carboxamide/*analogs & derivatives/*pharmacology MH - Animals MH - Biological Transport/drug effects MH - Enzyme Activation MH - Glucose/*metabolism MH - Isoenzymes/*physiology MH - Male MH - Mice MH - Mice, Inbred C57BL MH - Mitogen-Activated Protein Kinases/*physiology MH - Muscle, Skeletal/drug effects/metabolism MH - Phospholipase D/physiology MH - *Physical Conditioning, Animal MH - Protein Kinase C/*physiology MH - Rats MH - Rats, Sprague-Dawley MH - Ribonucleotides/*pharmacology EDAT- 2002/04/30 10:00 MHDA- 2002/08/07 10:01 CRDT- 2002/04/30 10:00 PHST- 2002/04/30 10:00 [pubmed] PHST- 2002/08/07 10:01 [medline] PHST- 2002/04/30 10:00 [entrez] AID - S0021-9258(19)66733-5 [pii] AID - 10.1074/jbc.M201152200 [doi] PST - ppublish SO - J Biol Chem. 2002 Jun 28;277(26):23554-62. doi: 10.1074/jbc.M201152200. Epub 2002 Apr 26.